Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1997 Jan 1;321(Pt 1):177–185. doi: 10.1042/bj3210177

Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.

L Pooley 1, Y Shakur 1, G Rena 1, M D Houslay 1
PMCID: PMC1218052  PMID: 9003417

Abstract

Cells of two human follicular thyroid carcinoma cell lines (FTC133, FTC236) were stably transfected with a cDNA encoding the PDE4A cAMP-specific phosphodiesterase (PDE) splice variant RD1 (RNPDE4A1A) so as to generate the cloned cell lines, FTC133A and FTC236A. This allowed the expression of a novel rolipram-inhibited cAMP-specific PDE activity in these cells. Unlike the parent cell lines in which Ca2+/calmodulin caused a profound activation (approx. 3-4-fold) of homogenate PDE activity, no such stimulation was evident in the RD1-expressing cell lines, indicating loss of PDE1 activity. Reverse transcriptase-PCR analysis indicated that this was due to the down-regulation of the PDE1C isoform. The novel PDE4 activity in transfected cells was located exclusively in the membrane fraction, as was immunoreactive RD1. Low concentrations of the detergent Triton X-100, but not high NaCl concentrations, allowed RD1 to be solubilized. Laser scanning confocal immunofluorescence analyses identified RD1 immunoreactivity in a discrete perinuclear region of these RD1-expressing transfected cell lines. A similar pattern of labelling was observed using the antiserum Tex1, which specifically identified the Golgi apparatus. Treatment of FTC133A cells with the Golgi-perturbing agents monensin and brefeldin A led to a similar redistribution of immunoreactive species detected using both the Tex1 and anti-RD1 antisera. It is suggested that the PDE4A splice variant RD1 contains a membrane-association signal which allows the targeted expression of RD1 within the Golgi complex of these human follicular thyroid carcinoma cell lines.

Full Text

The Full Text of this article is available as a PDF (424.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashton M. J., Cook D. C., Fenton G., Karlsson J. A., Palfreyman M. N., Raeburn D., Ratcliffe A. J., Souness J. E., Thurairatnam S., Vicker N. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J Med Chem. 1994 May 27;37(11):1696–1703. doi: 10.1021/jm00037a021. [DOI] [PubMed] [Google Scholar]
  2. Beavo J. A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995 Oct;75(4):725–748. doi: 10.1152/physrev.1995.75.4.725. [DOI] [PubMed] [Google Scholar]
  3. Bolger G. B., McPhee I., Houslay M. D. Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8. J Biol Chem. 1996 Jan 12;271(2):1065–1071. doi: 10.1074/jbc.271.2.1065. [DOI] [PubMed] [Google Scholar]
  4. Bolger G. B. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal. 1994 Nov;6(8):851–859. doi: 10.1016/0898-6568(94)90018-3. [DOI] [PubMed] [Google Scholar]
  5. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  6. Conti M., Iona S., Cuomo M., Swinnen J. V., Odeh J., Svoboda M. E. Characterization of a hormone-inducible, high affinity adenosine 3'-5'-cyclic monophosphate phosphodiesterase from the rat Sertoli cell. Biochemistry. 1995 Jun 27;34(25):7979–7987. doi: 10.1021/bi00025a003. [DOI] [PubMed] [Google Scholar]
  7. Conti M., Nemoz G., Sette C., Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev. 1995 Jun;16(3):370–389. doi: 10.1210/edrv-16-3-370. [DOI] [PubMed] [Google Scholar]
  8. Davis R. L., Takayasu H., Eberwine M., Myres J. Cloning and characterization of mammalian homologs of the Drosophila dunce+ gene. Proc Natl Acad Sci U S A. 1989 May;86(10):3604–3608. doi: 10.1073/pnas.86.10.3604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Erdogan S., Houslay M. D. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem J. 1997 Jan 1;321(Pt 1):165–175. doi: 10.1042/bj3210165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hoelting T., Zielke A., Siperstein A. E., Clark O. H., Duh Q. Y. Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro. Clin Exp Metastasis. 1994 Jul;12(4):315–323. doi: 10.1007/BF01753838. [DOI] [PubMed] [Google Scholar]
  11. Horton Y. M., Sullivan M., Houslay M. D. Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected]. Biochem J. 1995 Jun 1;308(Pt 2):683–691. doi: 10.1042/bj3080683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hölting T., Siperstein A. E., Clark O. H., Duh Q. Y. Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol. 1995 Feb;132(2):229–235. doi: 10.1530/eje.0.1320229. [DOI] [PubMed] [Google Scholar]
  13. Klausner R. D., Donaldson J. G., Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol. 1992 Mar;116(5):1071–1080. doi: 10.1083/jcb.116.5.1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Korman A. J., Frantz J. D., Strominger J. L., Mulligan R. C. Expression of human class II major histocompatibility complex antigens using retrovirus vectors. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2150–2154. doi: 10.1073/pnas.84.8.2150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  16. Lavan B. E., Lakey T., Houslay M. D. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. Biochem Pharmacol. 1989 Nov 15;38(22):4123–4136. doi: 10.1016/0006-2952(89)90694-1. [DOI] [PubMed] [Google Scholar]
  17. Loughney K., Martins T. J., Harris E. A., Sadhu K., Hicks J. B., Sonnenburg W. K., Beavo J. A., Ferguson K. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases. J Biol Chem. 1996 Jan 12;271(2):796–806. doi: 10.1074/jbc.271.2.796. [DOI] [PubMed] [Google Scholar]
  18. Manganiello V. C., Murata T., Taira M., Belfrage P., Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys. 1995 Sep 10;322(1):1–13. doi: 10.1006/abbi.1995.1429. [DOI] [PubMed] [Google Scholar]
  19. Marchmont R. J., Houslay M. D. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem J. 1980 May 1;187(2):381–392. doi: 10.1042/bj1870381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McPhee I., Pooley L., Lobban M., Bolger G., Houslay M. D. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem J. 1995 Sep 15;310(Pt 3):965–974. doi: 10.1042/bj3100965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Michie A. M., Lobban M., Müller T., Harnett M. M., Houslay M. D. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell Signal. 1996 Feb;8(2):97–110. doi: 10.1016/0898-6568(95)02032-2. [DOI] [PubMed] [Google Scholar]
  22. Milatovich A., Bolger G., Michaeli T., Francke U. Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse. Somat Cell Mol Genet. 1994 Mar;20(2):75–86. doi: 10.1007/BF02290677. [DOI] [PubMed] [Google Scholar]
  23. Méry P. F., Pavoine C., Pecker F., Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol. 1995 Jul;48(1):121–130. [PubMed] [Google Scholar]
  24. Nakamura N., Rabouille C., Watson R., Nilsson T., Hui N., Slusarewicz P., Kreis T. E., Warren G. Characterization of a cis-Golgi matrix protein, GM130. J Cell Biol. 1995 Dec;131(6 Pt 2):1715–1726. doi: 10.1083/jcb.131.6.1715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nicholson C. D., Challiss R. A., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci. 1991 Jan;12(1):19–27. doi: 10.1016/0165-6147(91)90484-a. [DOI] [PubMed] [Google Scholar]
  26. Nicholson C. D., Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma. Pulm Pharmacol. 1994 Feb;7(1):1–17. doi: 10.1006/pulp.1994.1001. [DOI] [PubMed] [Google Scholar]
  27. O'Connell J. C., McCallum J. F., McPhee I., Wakefield J., Houslay E. S., Wishart W., Bolger G., Frame M., Houslay M. D. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem J. 1996 Aug 15;318(Pt 1):255–261. doi: 10.1042/bj3180255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Orci L., Tagaya M., Amherdt M., Perrelet A., Donaldson J. G., Lippincott-Schwartz J., Klausner R. D., Rothman J. E. Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae. Cell. 1991 Mar 22;64(6):1183–1195. doi: 10.1016/0092-8674(91)90273-2. [DOI] [PubMed] [Google Scholar]
  29. Pelham H. R. Multiple targets for brefeldin A. Cell. 1991 Nov 1;67(3):449–451. doi: 10.1016/0092-8674(91)90517-3. [DOI] [PubMed] [Google Scholar]
  30. Podzuweit T., Nennstiel P., Müller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal. 1995 Sep;7(7):733–738. doi: 10.1016/0898-6568(95)00042-n. [DOI] [PubMed] [Google Scholar]
  31. Qiu Z., Tufaro F., Gillam S. Brefeldin A and monensin arrest cell surface expression of membrane glycoproteins and release of rubella virus. J Gen Virol. 1995 Apr;76(Pt 4):855–863. doi: 10.1099/0022-1317-76-4-855. [DOI] [PubMed] [Google Scholar]
  32. Raeburn D., Souness J. E., Tomkinson A., Karlsson J. A. Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma. Prog Drug Res. 1993;40:9–32. doi: 10.1007/978-3-0348-7147-1_3. [DOI] [PubMed] [Google Scholar]
  33. Scotland G., Houslay M. D. Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase. Biochem J. 1995 Jun 1;308(Pt 2):673–681. doi: 10.1042/bj3080673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Scott J. D., McCartney S. Localization of A-kinase through anchoring proteins. Mol Endocrinol. 1994 Jan;8(1):5–11. doi: 10.1210/mend.8.1.8152430. [DOI] [PubMed] [Google Scholar]
  35. Sette C., Vicini E., Conti M. The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J Biol Chem. 1994 Jul 15;269(28):18271–18274. [PubMed] [Google Scholar]
  36. Shakur Y., Pryde J. G., Houslay M. D. Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem J. 1993 Jun 15;292(Pt 3):677–686. doi: 10.1042/bj2920677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Shakur Y., Wilson M., Pooley L., Lobban M., Griffiths S. L., Campbell A. M., Beattie J., Daly C., Houslay M. D. Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem J. 1995 Mar 15;306(Pt 3):801–809. doi: 10.1042/bj3060801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Smith K. J., Scotland G., Beattie J., Trayer I. P., Houslay M. D. Determination of the structure of the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1) by 1H NMR and identification of the membrane association domain using chimeric constructs. J Biol Chem. 1996 Jul 12;271(28):16703–16711. doi: 10.1074/jbc.271.28.16703. [DOI] [PubMed] [Google Scholar]
  39. Sonnenburg W. K., Seger D., Beavo J. A. Molecular cloning of a cDNA encoding the "61-kDa" calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms. J Biol Chem. 1993 Jan 5;268(1):645–652. [PubMed] [Google Scholar]
  40. Spence S., Houslay M. D. The local anaesthetic benzyl alcohol attenuates the alpha 2-adrenoceptor-mediated inhibition of human platelet adenylate cyclase activity when stimulated by prostaglandin E1, but not that stimulated by forskolin. Biochem J. 1989 Dec 1;264(2):483–488. doi: 10.1042/bj2640483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Spence S., Rena G., Sweeney G., Houslay M. D. Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. Biochem J. 1995 Sep 15;310(Pt 3):975–982. doi: 10.1042/bj3100975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sullivan M., Egerton M., Shakur Y., Marquardsen A., Houslay M. D. Molecular cloning and expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IVA, cyclic AMP specific phosphodiesterase (hPDE-IVA-h6.1). Cell Signal. 1994 Sep;6(7):793–812. doi: 10.1016/0898-6568(94)00039-5. [DOI] [PubMed] [Google Scholar]
  43. Swinnen J. V., Joseph D. R., Conti M. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8197–8201. doi: 10.1073/pnas.86.21.8197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Szpirer C., Szpirer J., Rivière M., Swinnen J., Vicini E., Conti M. Chromosomal localization of the human and rat genes (PDE4D and PDE4B) encoding the cAMP-specific phosphodiesterases 3 and 4. Cytogenet Cell Genet. 1995;69(1-2):11–14. doi: 10.1159/000133927. [DOI] [PubMed] [Google Scholar]
  45. Thompson W. J., Appleman M. M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry. 1971 Jan 19;10(2):311–316. [PubMed] [Google Scholar]
  46. Torii S., Banno T., Watanabe T., Ikehara Y., Murakami K., Nakayama K. Cytotoxicity of brefeldin A correlates with its inhibitory effect on membrane binding of COP coat proteins. J Biol Chem. 1995 May 12;270(19):11574–11580. doi: 10.1074/jbc.270.19.11574. [DOI] [PubMed] [Google Scholar]
  47. Torphy T. J., DeWolf W. E., Jr, Green D. W., Livi G. P. Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions Suppl. 1993;43:51–71. doi: 10.1007/978-3-0348-7324-6_5. [DOI] [PubMed] [Google Scholar]
  48. Torphy T. J., Zhou H. L., Foley J. J., Sarau H. M., Manning C. D., Barnette M. S. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. J Biol Chem. 1995 Oct 6;270(40):23598–23604. doi: 10.1074/jbc.270.40.23598. [DOI] [PubMed] [Google Scholar]
  49. Verghese M. W., McConnell R. T., Lenhard J. M., Hamacher L., Jin S. L. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol. 1995 Jun;47(6):1164–1171. [PubMed] [Google Scholar]
  50. Wilson M., Sullivan M., Brown N., Houslay M. D. Purification, characterization and analysis of rolipram inhibition of a human type-IVA cyclic AMP-specific phosphodiesterase expressed in yeast. Biochem J. 1994 Dec 1;304(Pt 2):407–415. doi: 10.1042/bj3040407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Yan C., Bentley J. K., Sonnenburg W. K., Beavo J. A. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J Neurosci. 1994 Mar;14(3 Pt 1):973–984. doi: 10.1523/JNEUROSCI.14-03-00973.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Yan C., Zhao A. Z., Bentley J. K., Loughney K., Ferguson K., Beavo J. A. Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9677–9681. doi: 10.1073/pnas.92.21.9677. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES